You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The suit alleged that Precipio failed to meet the obligations of a securities agreement signed by Transgenomic, which it acquired last year.
The suit alleges that Precipio is required to pay more than $2 million in debt owed by Transgenomic, which it acquired last year.
The offering was a follow-on to a capital raise during the summer that brought in $6 million. The company's CEO said the additional financing was needed to execute on its business plan.
The company is offering units consisting of preferred stock and warrants to purchase shares of its common stock.
More than 90 percent of voting Transgenomic shareholders gave the go-ahead to the deal. Upon completion of the merger, the new firm will take on the Precipio name.
The company will use the funds to complete its merger with Precipio Diagnostics, which is expected to close in the second quarter.
The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.
LifeLabs will have a non-exclusive license to the technology and use it in its mutation enrichment platform for cancer testing.
Under the agreement, Precipio would become a wholly owned subsidiary of Transgenomic, which would then adopt the new name Precipio.
JoyingBio will distribute Transgenomic's multiplexed ICE COLD-PCR kits in China and Biotron Healthcare will do the same in India.
Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.
The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.
Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.